American Auto Surge
Tap into the unexpected strength of America's auto industry. This collection features carefully selected automakers, parts suppliers, and retailers benefiting from Ford's impressive 14.2% sales jump and robust consumer spending on vehicles.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
General Motors Co.
GM
Current price
$57.06
A direct competitor that also reported a 7% sales increase, General Motors benefits from the overall strength and consumer resilience in the U.S. auto...
A direct competitor that also reported a 7% sales increase, General Motors benefits from the overall strength and consumer resilience in the U.S. auto market.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
Ford's surprising 14.2% sales increase signals remarkable resilience in consumer spending on vehicles, especially high-margin trucks. This strength is creating a ripple effect throughout the auto industry, from manufacturers to parts suppliers to retailers – all positioned to benefit from this momentum.
What You Need to Know
This collection offers exposure across the entire automotive value chain. It includes major manufacturers like Ford and Toyota, critical parts suppliers such as Cummins and Dorman, and retailers like Penske. This diversity lets you capture growth at multiple points in the industry.
Why These Stocks
These companies were selected because they stand to directly benefit from increased vehicle production and sales. Each plays a specific role in the automotive ecosystem – from building the vehicles to supplying crucial components to selling and servicing them for consumers.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+14.22%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 14.22% over the next year.
Stocks Rated Buy by Analysts
11 of 14 assets in this group are rated Buy by professional analysts.
Group Growth vs Bank interest
This group averaged a 10.2% return last month, beating the typical 4% bank rate.
Why You'll Want to Watch These Stocks
Trucks Are Rolling Off Lots
High-margin trucks and SUVs are driving record sales, with Ford's F-Series alone seeing double-digit growth. This surge is putting cash in automakers' pockets when many expected a slowdown.
Consumer Spending Defies Expectations
Despite inflation concerns, Americans are still buying big-ticket vehicles. This unexpected resilience signals potential upside for the entire auto ecosystem that analysts may not have fully priced in yet.
The Ripple Effect Is Just Starting
Higher production volumes are now cascading through the supply chain. As manufacturers ramp up to meet demand, parts suppliers and retailers stand to benefit from this momentum for quarters to come.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.